NewsAI-assisted

Orchestra BioMed Appoints Dr. Vivek Reddy to Lead BACKBEAT Study

Dr. Vivek Reddy joins Orchestra BioMed to advance AVIM therapy for hypertension through pivotal clinical research.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Feb 19, 2025Updated Jun 26, 2025 · 2 min read
Orchestra BioMed Appoints Dr. Vivek Reddy to Lead BACKBEAT Study
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Orchestra BioMed has announced the appointment of Dr. Vivek Reddy as Executive Chairman of its BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. Dr. Reddy, a globally recognized expert in cardiac electrophysiology, will spearhead efforts to advance AVIM therapy, a device-based treatment designed to address uncontrolled hypertension in high-risk cardiovascular patients. His leadership will be instrumental in guiding the pivotal BACKBEAT study, fostering clinical adoption, and exploring further applications for Orchestra BioMed’s bioelectronic therapies.

Dr. Reddy, currently serving at The Mount Sinai Fuster Heart Hospital, brings extensive experience in electrophysiology, catheter ablation, and stroke prevention device therapies. His expanded role aims to enhance collaboration between clinical advisors and increase awareness of AVIM therapy within the medical community. Orchestra BioMed CEO David Hochman emphasized the significance of this appointment in driving innovation and delivering AVIM therapy to patients globally. As research continues, this partnership is expected to shape the future of cardiovascular treatment, offering a new approach to managing hypertension without reliance on patient adherence.

Explore How AVIM Therapy Now Holds 137 Global Patents

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →